Market Cap | 1.23B | P/E | - | EPS this Y | 5.90% | Ern Qtrly Grth | - |
Income | -220.01M | Forward P/E | -5.73 | EPS next Y | 6.60% | 50D Avg Chg | -1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 2.18 | EPS next 5Y | - | 52W High Chg | -28.00% |
Recommedations | 1.70 | Quick Ratio | 13.29 | Shares Outstanding | 68.32M | 52W Low Chg | 41.00% |
Insider Own | 4.74% | ROA | -25.74% | Shares Float | 43.76M | Beta | 1.21 |
Inst Own | 105.00% | ROE | -46.79% | Shares Shorted/Prior | 4.86M/6.06M | Price | 21.32 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 572,541 | Target Price | 15.50 |
Oper. Margin | - | Earnings Date | Nov 5 | Volume | 815,055 | Change | 3.80% |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
JP Morgan | Overweight | Sep 24, 24 |
HC Wainwright & Co. | Buy | Sep 16, 24 |
HC Wainwright & Co. | Buy | Sep 10, 24 |
Roth MKM | Buy | Aug 27, 24 |
JP Morgan | Overweight | Aug 13, 24 |
Barclays | Overweight | Jun 7, 24 |
HC Wainwright & Co. | Buy | Jun 7, 24 |
Barclays | Overweight | Dec 6, 23 |
HC Wainwright & Co. | Buy | Nov 13, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Xynos Konstantinos | Chief Medical Office.. Chief Medical Officer | Nov 16 | Sell | 10.92 | 7,313 | 79,858 | 112,714 | 11/17/23 |
Sarchi Christopher | Chief Commercial Off.. Chief Commercial Officer | Nov 16 | Sell | 10.92 | 5,255 | 57,385 | 72,245 | 11/17/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Sep 11 | Sell | 20.01 | 5,658 | 113,217 | 263,436 | 09/13/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Sep 11 | Option | 3.3 | 5,658 | 18,671 | 263,736 | 09/13/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Aug 22 | Sell | 20.01 | 18,600 | 372,186 | 263,436 | 08/24/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Aug 22 | Option | 9.4 | 18,600 | 174,840 | 282,036 | 08/24/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Aug 11 | Sell | 20 | 1,400 | 28,000 | 263,436 | 08/15/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Aug 11 | Option | 3.3 | 1,400 | 4,620 | 264,836 | 08/15/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Jul 10 | Sell | 21.38 | 20,000 | 427,600 | 263,436 | 07/11/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Jul 10 | Option | 9.4 | 20,000 | 188,000 | 283,436 | 07/11/23 |
Lewis Tanya | Chief Dev. Op. Offic.. Chief Dev. Op. Officer | Jun 13 | Sell | 23.78 | 12,860 | 305,811 | 135,293 | 06/15/23 |
Patel Sushil | Chief Strategy Offic.. Chief Strategy Officer | Jun 13 | Sell | 23.78 | 5,698 | 135,498 | 148,873 | 06/15/23 |
Patel Sushil | Chief Strategy Offic.. Chief Strategy Officer | May 16 | Sell | 18.05 | 15,575 | 281,129 | 154,571 | 05/18/23 |
Coffin Robert | President & Chief R&.. President & Chief R&D Officer | May 16 | Sell | 18.05 | 7,861 | 141,891 | 1,833,336 | 05/18/23 |
Lewis Tanya | Chief Dev. Op. Offic.. Chief Dev. Op. Officer | May 16 | Sell | 18.05 | 12,207 | 220,336 | 148,153 | 05/18/23 |
Love Colin | Chief Operating Offi.. Chief Operating Officer | May 16 | Sell | 18.05 | 10,775 | 194,489 | 794,960 | 05/18/23 |
Franchi Jean M. | Chief Financial Offi.. Chief Financial Officer | May 16 | Sell | 18.05 | 11,351 | 204,886 | 128,748 | 05/18/23 |
Xynos Konstantinos | Chief Medical Office.. Chief Medical Officer | May 16 | Sell | 18.05 | 771 | 13,917 | 120,027 | 05/18/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | May 16 | Sell | 18.05 | 5,966 | 107,686 | 263,436 | 05/18/23 |
Astley-Sparke Philip | Chief Executive Offi.. Chief Executive Officer | May 16 | Sell | 18.05 | 17,902 | 323,131 | 1,525,278 | 05/18/23 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Dec 09 | Option | 1.01 | 15,000 | 15,150 | 244,402 | 12/13/22 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | Dec 09 | Sell | 25.03 | 15,000 | 375,450 | 229,402 | 12/13/22 |
Love Colin | Chief Operating Offi.. Chief Operating Officer | May 16 | Sell | 14.59 | 6,324 | 92,267 | 765,735 | 05/18/22 |
Esposito Pamela | Chief Business Offic.. Chief Business Officer | May 16 | Sell | 14.59 | 3,507 | 51,167 | 229,402 | 05/18/22 |
Franchi Jean M. | Chief Financial Offi.. Chief Financial Officer | May 16 | Sell | 14.59 | 3,436 | 50,131 | 95,099 | 05/18/22 |
Lewis Tanya | Chief Dev. Op Office.. Chief Dev. Op Officer | May 16 | Sell | 14.59 | 5,473 | 79,851 | 120,360 | 05/18/22 |
Patel Sushil | Chief Commercial Off.. Chief Commercial Officer | May 16 | Sell | 14.59 | 10,687 | 155,923 | 130,146 | 05/18/22 |
Coffin Robert | President & Chief R&.. President & Chief R&D Officer | May 16 | Sell | 14.59 | 5,737 | 83,703 | 1,796,197 | 05/18/22 |
Astley-Sparke Philip | Chief Executive Offi.. Chief Executive Officer | May 16 | Sell | 14.59 | 9,632 | 140,531 | 1,401,080 | 05/18/22 |
Omega Fund IV, L.P. | 10% Owner 10% Owner | Mar 14 | Option | 9.78 | 16,500 | 161,370 | 4,779,880 | 03/16/22 |
Omega Fund IV, L.P. | 10% Owner 10% Owner | Mar 14 | Sell | 15.48 | 106,500 | 1,648,620 | 4,673,380 | 03/16/22 |
Omega Fund IV, L.P. | Director Director | Nov 16 | Sell | 33.5 | 2,594 | 86,899 | 4,808,804 | 11/18/21 |
Omega Fund IV, L.P. | Director Director | Nov 12 | Sell | 33.66 | 24,017 | 808,412 | 4,811,398 | 11/16/21 |
Love Colin | Chief Operating Offi.. Chief Operating Officer | Oct 15 | Sell | 30.35 | 30,000 | 910,500 | 745,809 | 10/19/21 |